529 related articles for article (PubMed ID: 31599133)
1. FGF23 and Associated Disorders of Phosphate Wasting.
Gohil A; Imel EA
Pediatr Endocrinol Rev; 2019 Sep; 17(1):17-34. PubMed ID: 31599133
[TBL] [Abstract][Full Text] [Related]
2. Phosphatonins: From Discovery to Therapeutics.
Kritmetapak K; Kumar R
Endocr Pract; 2023 Jan; 29(1):69-79. PubMed ID: 36210014
[TBL] [Abstract][Full Text] [Related]
3. New Therapies for Hypophosphatemia-Related to FGF23 Excess.
Athonvarangkul D; Insogna KL
Calcif Tissue Int; 2021 Jan; 108(1):143-157. PubMed ID: 32504139
[TBL] [Abstract][Full Text] [Related]
4. FGF23-related hypophosphatemic rickets/osteomalacia: diagnosis and new treatment.
Fukumoto S
J Mol Endocrinol; 2021 Feb; 66(2):R57-R65. PubMed ID: 33295878
[TBL] [Abstract][Full Text] [Related]
5. [Rickets/Osteomalacia. Anti-FGF23 antibody therapy in patients with FGF23-related hypophosphatemic rickets and osteomalacia.].
Kinoshita Y
Clin Calcium; 2018; 28(10):1373-1379. PubMed ID: 30269120
[TBL] [Abstract][Full Text] [Related]
6. X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment.
Kinoshita Y; Fukumoto S
Endocr Rev; 2018 Jun; 39(3):274-291. PubMed ID: 29381780
[TBL] [Abstract][Full Text] [Related]
7. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia.
Carpenter TO; Imel EA; Ruppe MD; Weber TJ; Klausner MA; Wooddell MM; Kawakami T; Ito T; Zhang X; Humphrey J; Insogna KL; Peacock M
J Clin Invest; 2014 Apr; 124(4):1587-97. PubMed ID: 24569459
[TBL] [Abstract][Full Text] [Related]
8. X-Linked Hypophosphatemic Rickets: Multisystemic Disorder in Children Requiring Multidisciplinary Management.
Baroncelli GI; Mora S
Front Endocrinol (Lausanne); 2021; 12():688309. PubMed ID: 34421819
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis and management of X-linked hypophosphatemia in children and adolescent in the Gulf Cooperation Council countries.
Al Juraibah F; Al Amiri E; Al Dubayee M; Al Jubeh J; Al Kandari H; Al Sagheir A; Al Shaikh A; Beshyah SA; Deeb A; Habeb A; Mustafa M; Zidan H; Mughal MZ
Arch Osteoporos; 2021 Mar; 16(1):52. PubMed ID: 33660084
[TBL] [Abstract][Full Text] [Related]
10. Hypophosphatemic rickets: lessons from disrupted FGF23 control of phosphorus homeostasis.
Goldsweig BK; Carpenter TO
Curr Osteoporos Rep; 2015 Apr; 13(2):88-97. PubMed ID: 25620749
[TBL] [Abstract][Full Text] [Related]
11. Rickets guidance: part II-management.
Haffner D; Leifheit-Nestler M; Grund A; Schnabel D
Pediatr Nephrol; 2022 Oct; 37(10):2289-2302. PubMed ID: 35352187
[TBL] [Abstract][Full Text] [Related]
12. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis.
Insogna KL; Briot K; Imel EA; Kamenický P; Ruppe MD; Portale AA; Weber T; Pitukcheewanont P; Cheong HI; Jan de Beur S; Imanishi Y; Ito N; Lachmann RH; Tanaka H; Perwad F; Zhang L; Chen CY; Theodore-Oklota C; Mealiffe M; San Martin J; Carpenter TO;
J Bone Miner Res; 2018 Aug; 33(8):1383-1393. PubMed ID: 29947083
[TBL] [Abstract][Full Text] [Related]
13. Congenital Conditions of Hypophosphatemia Expressed in Adults.
Marcucci G; Brandi ML
Calcif Tissue Int; 2021 Jan; 108(1):91-103. PubMed ID: 32409880
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of burosumab in two patients with cutaneous skeletal hypophosphatemia syndrome.
Sugarman J; Maruri A; Hamilton DJ; Tabatabai L; Luca D; Cimms T; Krolczyk S; Roberts MS; Carpenter TO
Bone; 2023 Jan; 166():116598. PubMed ID: 36341949
[TBL] [Abstract][Full Text] [Related]
15. Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia.
Linglart A; Imel EA; Whyte MP; Portale AA; Högler W; Boot AM; Padidela R; Van't Hoff W; Gottesman GS; Chen A; Skrinar A; Scott Roberts M; Carpenter TO
J Clin Endocrinol Metab; 2022 Feb; 107(3):813-824. PubMed ID: 34636899
[TBL] [Abstract][Full Text] [Related]
16. Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations.
Imel EA; DiMeglio LA; Hui SL; Carpenter TO; Econs MJ
J Clin Endocrinol Metab; 2010 Apr; 95(4):1846-50. PubMed ID: 20157195
[TBL] [Abstract][Full Text] [Related]
17. Improvement in the mobility of a patient with fibroblast growth factor 23-related hypophosphatemic osteomalacia and decompensated liver cirrhosis in response to burosumab: a case report.
Toi N; Imanishi Y; Nagata Y; Kurajoh M; Morioka T; Shoji T; Shinto Y; Emoto M
Endocr J; 2023 Apr; 70(4):419-426. PubMed ID: 36575021
[TBL] [Abstract][Full Text] [Related]
18. Burosumab vs Phosphate/Active Vitamin D in Pediatric X-Linked Hypophosphatemia: A Subgroup Analysis by Dose Level.
Imel EA; Glorieux FH; Whyte MP; Portale AA; Munns CF; Nilsson O; Simmons JH; Padidela R; Namba N; Cheong HI; Pitukcheewanont P; Sochett E; Högler W; Muroya K; Tanaka H; Gottesman GS; Biggin A; Perwad F; Chen A; Roberts MS; Ward LM
J Clin Endocrinol Metab; 2023 Oct; 108(11):2990-2998. PubMed ID: 37084401
[TBL] [Abstract][Full Text] [Related]
19. X-linked hypophosphatemia and burosumab: Practical clinical points from the French experience.
Bacchetta J; Rothenbuhler A; Gueorguieva I; Kamenicky P; Salles JP; Briot K; Linglart A
Joint Bone Spine; 2021 Oct; 88(5):105208. PubMed ID: 34102329
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
